Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term TMC125 extension in HIV-1 infected subjects
2005-000712-27Phase 2Completed
- Sponsor
- Tibotec
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etravirine in Human immunodeficiency virus infection type 1, sponsored by Tibotec. Primary endpoint: Long-term safety and tolerability of TMC125. Started Jun 2005; status: completed.
02
Drugs
etravirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2005-000712-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000712-27.